Comparison of patients with SLE with low and high PS+ REVs
| Demographic characteristics | PS+ REV | |||
| Low | High | Pvalue | ||
| Gender | Female | 44 (88) | 41 (79) | 0.2897 |
| Age, years | 52.00 (41.00; 62.00) | 50.50 (37.50; 59.00) | 0.5592 | |
| BMI | 25.35 (22.43; 29.04) | 23.59 (21.46; 28.50) | 0.1062 | |
| Disease duration, years | 7.93 (0.76; 21.64) | 3.58 (1.41; 15.87) | 0.1426 | |
| Onset | Incident | 16 (32) | 13 (25) | 0.5124 |
| Prevalent | 34 (68) | 39 (75) | ||
| APS | 4 (8) | 12 (23) | 0.0551 | |
| Clinical characteristics | ||||
| SLEDAI | 2.00 (0.00; 6.00) | 1.50 (0.00; 4.00) | 0.0776 | |
| Platelet, 109 /L | 242.00 (195.00; 291.00) | 202.00 (176.50; 246.00) | 0.0262 | |
| MPV, fL | 8.70 (8.00; 10.00) | 8.90 (8.05; 9.55) | 0.6992 | |
| Haemoglobin, g/L | 129.00 (121.00; 137.00) | 131.00 (124.00; 138.00) | 0.3264 | |
| CRP, mg/L | 2.90 (1.21; 3.42) | 2.00 (1.00; 5.00) | 0.7683 | |
| ESR, mm/hour | 8.00 (4.00; 20.00) | 6.00 (3.00; 14.00) | 0.1674 | |
| Lupus anticoagulant | Presence | 4 (10) | 7 (15) | 0.5374 |
| Anticardiolipin IGG | Abnormal | 3 (8) | 10 (20) | 0.0674 |
| Equivocal | 2 (5) | 0 (0) | ||
| Anticardiolipin IGM | Abnormal | 3 (8) | 9 (18) | 0.1633 |
| Equivocal | 1 (3) | 0 (0) | ||
| Anti-β2GPI IGG | Abnormal | 1 (3) | 7 (14) | 0.1306 |
| Anti-β2GPI IGM | Abnormal | 4 (11) | 11 (22) | 0.2521 |
| Laboratory measurements | ||||
| ATX, ng/mL | 227.75 (183.10; 295.30) | 274.50 (207.83; 408.73) | 0.0318 | |
| PEVs, EVs/µL | 2419 (1012; 4566) | 4853 (2532; 8230) | 0.0006 | |
| PS+ PEVs, EVs/µL | 2042 (866; 4051) | 4384 (2238; 7696) | 0.0006 | |
| REVs, EVs/µL | 842 (426; 1387) | 4436 (3064; 7166) | <0.0001 | |
| ACR criteria | ||||
| Arthritis | 37 (76) | 42 (84) | 0.3262 | |
| Thrombocytopaenia | 9 (18) | 15 (30) | 0.2414 | |
| Malar rash | 17 (35) | 9 (18) | 0.0705 | |
| Discoid rash | 11 (22) | 7 (14) | 0.3080 | |
| Haemolytic anaemia | 3 (6) | 1 (2) | 0.3622 | |
| Renal disorder | 12 (24) | 13 (26) | 1.0000 | |
| Cardiovascular damages | ||||
| History of thrombosis | 2 (4) | 10 (19) | 0.0283 | |
| Medication | ||||
| NSAID/ Cox-II Inhibitors | 14 (28) | 11 (21) | 0.4931 | |
| Prednisone | 8 (16) | 13 (25) | 0.3299 | |
| Immunomodulators | 42 (86) | 44 (88) | 0.7742 | |
Continuous variables are presented as median (IQR), pvalue based on Wilcoxon Mann Whitney test. Categorical variables are presented as n (%), pvalue based on exact Pearson χ² test. Significant pvalues are in bold.
ACR, American College of Rheumatology; APS, antiphospholipid syndrome; ATX, autotaxin; BMI, body mass index; CIMT, carotid intima-media thickness; CRP, C reactive protein; DMARD, disease modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; EV, extracellular vesicle; MPV, mean platelet volume; NSAID, non-steroidal anti-inflammatory drug; PEV, platelet EV; PS+, phosphatidylserine positive; REV, red blood cell EV; SLE, systemic lupus erythematosus; SLEDAI, SLE disease activity index.